Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® cancer therapy, has appointed Nadav Kidron to its Board of Directors. Kidron, who currently serves as President, CEO, and Chairman of Oramed Pharmaceuticals, joins following a strategic investment between Alpha Tau and an Oramed affiliate. With extensive experience leading a public company in therapeutic innovation, Kidron brings valuable expertise as Alpha Tau progresses toward commercialization. His background includes leadership roles at MDG Real Estate Global, Israel Advanced Technology Industries Organization, and previous directorship at Entera Bio. Kidron holds an LL.B. and International MBA from Bar Ilan University.
Alpha Tau Medical (NASDAQ: DRTS), sviluppatore della terapia oncologica Alpha DaRT®, ha nominato Nadav Kidron nel suo Consiglio di Amministrazione. Kidron, attualmente Presidente, CEO e Presidente del Consiglio di Oramed Pharmaceuticals, si unisce in seguito a un investimento strategico tra Alpha Tau e una società affiliata a Oramed. Con una vasta esperienza nella guida di società pubbliche nel campo dell'innovazione terapeutica, Kidron apporta competenze preziose mentre Alpha Tau avanza verso la commercializzazione. Il suo percorso professionale include ruoli di leadership presso MDG Real Estate Global, Israel Advanced Technology Industries Organization e una precedente direzione in Entera Bio. Kidron è in possesso di una laurea in giurisprudenza (LL.B.) e un MBA internazionale conseguiti presso l'Università Bar Ilan.
Alpha Tau Medical (NASDAQ: DRTS), desarrollador de la terapia contra el cáncer Alpha DaRT®, ha nombrado a Nadav Kidron en su Junta Directiva. Kidron, quien actualmente es Presidente, CEO y Presidente de Oramed Pharmaceuticals, se une tras una inversión estratégica entre Alpha Tau y una afiliada de Oramed. Con amplia experiencia liderando una empresa pública en innovación terapéutica, Kidron aporta valiosos conocimientos mientras Alpha Tau avanza hacia la comercialización. Su trayectoria incluye cargos de liderazgo en MDG Real Estate Global, Israel Advanced Technology Industries Organization y una dirección previa en Entera Bio. Kidron posee una licenciatura en Derecho (LL.B.) y un MBA internacional de la Universidad Bar Ilan.
Alpha Tau Medical (NASDAQ: DRTS)는 Alpha DaRT® 암 치료제를 개발한 회사로, Nadav Kidron을 이사회 멤버로 임명했습니다. 현재 Oramed Pharmaceuticals의 사장, CEO, 회장을 맡고 있는 Kidron은 Alpha Tau와 Oramed 계열사 간의 전략적 투자 후 합류했습니다. 치료 혁신 분야의 상장 기업을 이끈 폭넓은 경험을 바탕으로 Kidron은 Alpha Tau가 상용화를 향해 나아가는 데 중요한 전문성을 제공합니다. 그의 경력에는 MDG Real Estate Global, Israel Advanced Technology Industries Organization에서의 리더십 역할과 Entera Bio에서의 이전 이사직이 포함됩니다. Kidron은 Bar Ilan 대학교에서 법학 학위(LL.B.)와 국제 MBA를 취득했습니다.
Alpha Tau Medical (NASDAQ : DRTS), développeur de la thérapie anticancéreuse Alpha DaRT®, a nommé Nadav Kidron à son Conseil d'administration. Kidron, qui est actuellement Président, CEO et Président d'Oramed Pharmaceuticals, rejoint l'entreprise suite à un investissement stratégique entre Alpha Tau et une filiale d'Oramed. Fort d'une vaste expérience à la tête d'une société cotée spécialisée dans l'innovation thérapeutique, Kidron apporte une expertise précieuse alors qu'Alpha Tau progresse vers la commercialisation. Son parcours inclut des postes de direction chez MDG Real Estate Global, Israel Advanced Technology Industries Organization, ainsi qu'une précédente fonction d'administrateur chez Entera Bio. Kidron est titulaire d'un LL.B. et d'un MBA international de l'Université Bar Ilan.
Alpha Tau Medical (NASDAQ: DRTS), Entwickler der Krebsbehandlung Alpha DaRT®, hat Nadav Kidron in seinen Vorstand berufen. Kidron, der derzeit Präsident, CEO und Vorsitzender von Oramed Pharmaceuticals ist, tritt nach einer strategischen Investition zwischen Alpha Tau und einer Oramed-Tochtergesellschaft bei. Mit umfangreicher Erfahrung in der Führung eines börsennotierten Unternehmens im Bereich therapeutischer Innovation bringt Kidron wertvolles Fachwissen ein, während Alpha Tau auf die Kommerzialisierung zusteuert. Sein Werdegang umfasst Führungspositionen bei MDG Real Estate Global, Israel Advanced Technology Industries Organization und eine frühere Direktorenrolle bei Entera Bio. Kidron besitzt einen LL.B. und einen internationalen MBA von der Bar Ilan Universität.
- Strategic investment secured from Oramed affiliate
- Addition of experienced biotech executive with public company leadership to the Board
- Progress towards commercialization of Alpha DaRT® cancer therapy
- None.
JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, and Chairman of the Board of Oramed Pharmaceuticals Inc., (“Oramed”), has been appointed to the Company’s Board of Directors (“Board”). The appointment follows the recent closing of a strategic investment between the Company and an affiliate of Oramed.
“Nadav is a fantastic addition to the Board,” said Company CEO and Chairman of the Board Mr. Uzi Sofer. “He has spent many years in a position much like ours, at the helm of a public company innovating a therapeutic modality for patients, and I am sure that he will prove to be an immensely valuable asset to the Company in executing our strategy as we continue to move closer towards commercialization. We look forward to benefitting from his insights and experience in the coming years.”
“I am delighted to join Alpha Tau’s Board of Directors,” commented Mr. Kidron. “The Company is making incredible strides towards revolutionizing the field of oncology therapeutics, and I look forward to contributing to that critical mission.”
Mr. Kidron was appointed President, Chief Executive Officer and director of Oramed in March 2006, and Chairman of the board effective as of June 30, 2022. He is also Chairman of the board of MDG Real Estate Global, Ltd., director of Israel Advanced Technology Industries Organization and until 2016 was a director of Entera Bio Ltd. In 2009, he was a fellow at the Merage Foundation for U.S.-Israel Trade Programs for executives in the life sciences field. From 2003 to 2006, Mr. Kidron was the managing director of the Institute of Advanced Jewish Studies at Bar Ilan University. From 2001 to 2003, he was a legal intern at Wine, Mishaiker & Ernstoff Law Offices in Jerusalem, Israel. Mr. Kidron holds an LL.B. and an International MBA from Bar Ilan University, Israel.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including "anticipate," "being," "will," "plan," "may," "continue," and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Alpha Tau's current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau's ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau's limited operating history; (iii) Alpha Tau's incurrence of significant losses to date; (iv) Alpha Tau's need for additional funding and ability to raise capital when needed; (v) Alpha Tau's limited experience in medical device discovery and development; (vi) Alpha Tau's dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau's clinical studies to predict final study results; (viii) failure of Alpha Tau's early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau's ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau's Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau's exposure to patent infringement lawsuits; (xii) Alpha Tau's ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq's listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important factors discussed under the caption "Risk Factors" in Alpha Tau's annual report filed on form 20-F with the SEC on March 12, 2025, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau's views as of any date subsequent to the date of this press release.
Investor Relations Contact:
IR@alphatau.com
FAQ
Who is Nadav Kidron and what is his role at Alpha Tau Medical (DRTS)?
What is the relationship between Alpha Tau Medical (DRTS) and Oramed?
What is Alpha Tau Medical's (DRTS) main product?
What experience does Nadav Kidron bring to Alpha Tau Medical (DRTS)?
